Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.

@article{Ren2018CardiovascularBO,
  title={Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon.},
  author={Dylan Y Ren and Yingmei Zhang},
  journal={Current drug targets},
  year={2018},
  volume={19 9},
  pages={
          1051-1057
        }
}
Cardiovascular complications are among the main reasons for the high morbidity and mortality in patients with type 2 diabetes, making the management of cardiovascular complications an integral component in the treatment of type 2 diabetes. Along the same line, the US Food and Drug Administration mandated all new diabetic drugs and therapies have a safe cardiovascular profile. Among various drugs available for the treatment against type 2 diabetes, the sodium-glucose cotransporter 2 (SGLT2… Expand
New Therapeutic Approaches in the Management of Cardiometabolic Diseases: Bringing the Concepts Together.
TLDR
This special issue of “Current Drug Target” on “Drug discovery and development in the management cardiometabolic diseases” is presented to discuss a number of new therapeutic options in the field to identify and develop novel diagnostic and therapeutic techniques to better manage the cardiovascular risk in cardiometric diseases. Expand
A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro
TLDR
It is indicated that Dap protects cardiac myocytes from damage caused by hyperglycemia through suppressing NADPH oxidase-mediated oxidative stress. Expand